
What is claimed is:


1. A compound of Formula (I):




(I)

or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof,


wherein each of ring A and ring B is, independently, one of the following formulas:




formula (IIa);




formula (IIb);




formula (IIc);




formula (IId);



formula (IIe);



formula (IIf); or



formula (IIg);

indicates the point of attachment to Linker;

Linker is $–(CH_2)_r$-, $-(CH_2)_p$-X-$(CH_2)_q$-, or $-(CH_2)_p$-CH=CH-$(CH_2)_q$-;

X is NR^6, NHC(=O), C(=O)NH, O, SO_2, a substituted or unsubstituted aryl ring, substituted or unsubstituted heteroaryl ring, substituted or unsubstituted heterocyclic ring, or substituted or unsubstituted cyclic ring;

ring C is a cyclopropyl ring or a cyclobutyl ring;

each of the dotted bonds ------ between $-C(R^1)-$ and $-N(R^2)-$ is, independently, a single bond or a double bond;

when the dotted bond is a single bond, each R^1 is, independently, H or OH, and each R^2 is H;

when the dotted bond is a double bond, each R^1 is H, and each R^2 is absent;

each of R^3 and R^4 is, independently, H, NH_2, NR^aR^b, OH, $C_{1\text{-}4}$ alkyl, $C_{1\text{-}4}$ alkoxy, or aryl;

R^a and R^b are each independently H or $C_{1\text{-}4}$ alkyl;

R^5 is H, $C_{1\text{-}4}$ alkyl, $C_{1\text{-}4}$ alkoxy, or aryl;

R^6 is H, or $C_{1\text{-}4}$ alkyl;

each of m, n, and o is, independently, 1 or 2;


each of r, p, and q, is, independently, an integer from 1 to 8; and

the sum of p and q is an integer from 1 to 8.


2. The compound of claim 1, wherein Linker is $–(CH_2)_r$-, ring A is formula (IIa), and ring B is formula (IIb).

3. The compound of claim 1, wherein Linker is $–(CH_2)_p$-X-$(CH_2)_q$- or $-(CH_2)_p$-CH=CH-$(CH_2)_q$-, ring A is formula (IIa), m in ring A is 2, and ring B is one of formulas (IIa), (IIb), (IIc), (IId), (IIe), (IIf), and (IIg).


4. The compound of claim 1, wherein Linker is $-(CH_2)_p$-X-$(CH_2)_q$- or $-(CH_2)_p$-CH=CH-$(CH_2)_q$-, ring A is formula (IIa), m in ring A is 1, ring B is one of formulas (IIa), (IIb), (IIc), (IId), (IIe), (IIf), and (IIg), and formula (IIc) is formula (IIc3) or formula (IIc4):



formula (IIc3), or

















formula (IIc4).

5. The compound of claim 1, wherein X is O, NR^6, NHC(=O), -(*m*-C_6H_4)-, , or 

.

6. The compound of claim 1, wherein Linker is $-(CH_2)_r$- and r is 3 or 5.

7. The compound of claim 1, wherein Linker is $-(CH_2)_p$-O-$(CH_2)_q$- or $-(CH_2)_p$-NH-$(CH_2)_q$-, and the sum of p and q is 4.


8. The compound of claim 1, wherein Linker is , , , , , , , , , , , , , or ; and the sum of p and q is 2.


9. The compound of claim 5, wherein Linker is  and the sum of p and q is 2.









10. The compound of claim 1, wherein Linker is -$(CH_2)_p$-CH=CH-$(CH_2)_q$- and the sum of p and q is 3.









11. The compound of claim 1, wherein ring B is of formula (IIa) and ring A is of formula (IIb).









12. The compound of claim 1, wherein the compound is








,


,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,



,


, or


, or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof.


13. The compound of claim 1, wherein ring A and ring B are different.

14. A compound of Formula B(i) or B(ii):



Formula B(i)


or




Formula B(ii)

, or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof, wherein:


each of ring A and ring B is, independently, one of the following formulas:




formula (IIIa);




formula (IIIb);




formula (IIIc);




formula (IIId);



formula (IIIe);



formula (IIIf); or



(IIIg),

indicates the point of attachment to Linker or Ab Linker;

Linker is $–(CH_2)_r$-, $-(CH_2)_p$-X-$(CH_2)_q$-, or $-(CH_2)_p$-CH=CH-$(CH_2)_q$-;

X is NR^6, NHC(=O), C(=O)NH, O, SO_2, a substituted or unsubstituted aryl ring, substituted or unsubstituted heteroaryl ring, substituted or unsubstituted heterocyclic ring, or substituted or unsubstituted cyclic ring;

ring C is a cyclopropyl ring or a cyclobutyl ring;

each of the dotted bonds between $-C(R^1)-$ and $-N(R^2)-$ is, independently, a single bond or a double bond;

when the dotted bond is a single bond, each R^1 is, independently, H or OH, and each R^2 is H;

when the dotted bond is a double bond, each R^1 is, independently, H, and each R^2 is absent;

each of R^3 and R^4 is, independently, H, NH_2, NR^aR^b, OH, C_{1-4} alkyl, C_{1-4} alkoxyl, or aryl;

R^a and R^b are each independently H or C_{1-4} alkyl;

R^5 is H, C_{1-4} alkyl, C_{1-4} alkoxyl, or aryl;

R^6 is H or C_{1-4} alkyl;


each of m, n, and o is, independently, 1 or 2;

each of r, p, and q, is, independently, an integer from 1 to 8;

the sum of p and q is an integer from 1 to 8; and

Ab Linker is a compound able to join ring A or ring B to a binding agent.


15. The compound of claim 14, wherein Ab Linker has the following formula:




,

wherein # indicates the point of attachment to ring A or ring B.

16. The compound of claim 14, wherein the compound has the following formula:




or



,


or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof.

17. A conjugate of Formula A(i) or A(ii):




Formula A(i)

or




Formula A(ii) , or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof, wherein:


each of ring A and ring B is, independently, one of the following formulas:




formula (IIIa);




formula (IIIb);




formula (IIIc);




formula (IIId);



formula (IIIe);



formula (IIIf); or



(IIIg),

~~~ indicates the point of attachment to Linker or Ab Linker;

Linker is $-(CH_2)_r-$, $-(CH_2)_p-X-(CH_2)_q-$, or $-(CH_2)_p-CH=CH-(CH_2)_q-$;

X is NR^6, NHC(=O), C(=O)NH, O, SO_2, a substituted or unsubstituted aryl ring, substituted or unsubstituted heteroaryl ring, substituted or unsubstituted heterocyclic ring, or substituted or unsubstituted cyclic ring;

ring C is a cyclopropyl ring or a cyclobutyl ring;

each of the dotted bonds ------ between $-C(R^1)-$ and $-N(R^2)-$ is, independently, a single bond or a double bond;

when the dotted bond is a single bond, each R^1 is, independently, H or OH, and each R^2 is H;

when the dotted bond is a double bond, each R^1 is, independently, H, and each R^2 is absent;

each of R^3 and R^4 is, independently, H, NH_2, NR^aR^b, OH, C_{1-4} alkyl, C_{1-4} alkoxyl, or aryl;

R^a and R^b are each independently H or C_{1-4} alkyl;

R^5 is H, C_{1-4} alkyl, C_{1-4} alkoxyl, or aryl;

R^6 is H or C_{1-4} alkyl;

each of m, n, and o is, independently, 1 or 2;
~~~

each of r, p, and q, is, independently, an integer from 1 to 8;


the sum of p and q is an integer from 1 to 8;

Ab Linker is a compound that joins Ab to ring A or ring B;

Ab is a binding agent selected from a humanized, chimeric, or human antibody, or an antigen binding fragment thereof; and

subscript x is from 1 to 15.


18. The conjugate of claim 17, wherein Ab Linker has the following formula:




,

wherein ~~~* indicates the point of attachment to Ab, and ~~~# indicates the point of attachment to ring A or ring B.

19. The conjugate of claim 17, wherein the conjugate has the following formula:



or




,

or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof.


20. The conjugate of claim 19, wherein subscript x is about 2.

21. The conjugate of claim 20, wherein the conjugate has the following formula:



1.97

or



2
,

or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof.

22. A pharmaceutical composition comprising the conjugate of claim 17, or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient.